Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 13/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | PTPRF | P10586 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466849 | 0.90 | PTPN1 (0.53) | DAGLAPTPN1PTPRFPTPRAPTPN7 | |
| SCHEMBL4455545 | 0.88 | PTPN1 (0.49) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL4467517 | 0.87 | PTPN1 (0.51) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL4265325 | 0.86 | PTPN1 (0.57) | DAGLAPTPN1PTPRFPTPRAPTPN7 | |
| SCHEMBL4460686 | 0.83 | PTPN1 (0.49) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL4854844 | 0.80 | PTPN1 (0.43) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL5338389 | 0.75 | PTPN1 (0.49) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL4462116 | 0.73 | PTPN1 (0.50) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL4455532 | 0.72 | PTPN1 (0.47) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL4459383 | 0.72 | KEAP1 (0.48) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006525365-A | — | — | 2006-11-09 | — | — | JP | claimed |
| EP-1620422-A2 | PHENYL SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-01 | — | — | EP | claimed |
| US-20050004369-A1 | Phenyl substituted carboxylic acids | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | claimed |
| WO-2004099170-A2 | PHENYL SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | claimed |
| US-7524878-B2 | Phenyl substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICALS DISCOVERY LLC (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524878-B2 | Phenyl substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICALS DISCOVERY LLC (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524878-B2 | Phenyl substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICALS DISCOVERY LLC (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050004369-A1 | Phenyl substituted carboxylic acids | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004369-A1 | Phenyl substituted carboxylic acids | PTPA, PTPRS, PTPRO | DAGLA 1744/4885CYP3A4 2962/4885CYP2D6 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.